In December 2012, API (norfloxacin) passed the site GMP inspection by South Korea KFDA.
In February 2013, API (norfloxacin) passed the site GMP inspection by Slovenia Jazmp.
In January 2014, tablet and capsule Passed the new GMP site-inspection from CFDA.
In April 2014, six API passed the new GMP certification by CFDA.
In August 2014, pass the site re-certification by FDA of the USA.
In February 2015, the new added workshop of API (atorvastatin calcium) passed the GMP certification by CFDA.
In July 2015, API (rina thiazole amine) passed the GMP certification by Mexican COFEPRIS.